ich
guidelin
defin
gener
framework
immunotox
evalu
biotechnologyderiv
pharmaceut
human
pharmaceut
respect
sever
unpredict
advers
event
dramat
show
recent
year
immun
system
critic
aspect
drug
safeti
framework
need
revisit
enhanc
predict
nonclin
immun
safeti
evalu
safeti
immunopharmacolog
deem
contribut
await
improv
enabl
earli
screen
potenti
drug
candid
induc
unexpect
immunosuppress
immunostimulatori
effect
well
nonimmunemedi
hypersensit
reaction
dedic
safeti
immunopharmacolog
also
gener
mechanist
data
determin
relev
addit
immunotox
studi
conduct
immunolog
assay
model
consid
use
context
safeti
pharmacolog
studi
present
well
perspect
time
develop
immun
system
far
seldom
consid
target
safeti
pharmacolog
studi
drug
candid
thu
ich
guidelin
briefli
mention
immun
system
exampl
organ
system
whose
function
investig
context
followup
supplement
safeti
pharmacolog
studi
human
pharmaceut
ich
recent
year
sever
unpredict
immunerel
advers
event
howev
dramat
show
immun
system
consid
critic
aspect
drug
safeti
illustr
exampl
advers
event
includ
report
infecti
complic
eg
tuberculosi
varieti
opportunist
infect
patient
treat
drug
rychli
dipiro
reactiv
jc
viru
result
progress
multifoc
leukoencephalopathi
suspect
consequ
natalizumab
treatment
multipl
sclerosi
patient
et
al
socal
cytokin
storm
healthi
volunt
enrol
phase
clinic
trial
monoclon
antibodi
suntharalingam
et
al
advers
event
demonstr
despit
signific
progress
nonclin
immun
safeti
evalu
last
two
decad
much
remain
done
improv
procedur
strategi
current
use
rapid
develop
novel
biolog
biopharmaceut
major
target
immun
system
role
safeti
immunopharmacolog
expect
increas
significantli
near
futur
inde
two
major
limit
nonclin
safeti
evalu
biolog
immunogen
potenti
result
gener
neutral
antidrug
antibodi
turn
limit
durat
relev
nonclin
toxic
studi
ponc
et
al
ii
lack
relev
convent
anim
speci
tent
replac
transgen
diseas
anim
regulatori
toxic
studi
face
mani
challeng
hurdl
bussier
et
al
therefor
safeti
immunopharmacolog
studi
expect
serv
use
addon
gener
relev
miss
data
standard
toxic
studi
unabl
gener
moreov
search
small
molecular
entiti
target
immun
system
treat
varieti
diseas
rang
cancer
allerg
autoimmun
diseas
rapidli
expand
tsitoura
tassio
erter
et
al
nichola
giannetti
alsanousi
fried
muraro
therefor
need
dedic
exploratori
mechanist
immunopharmacolog
studi
address
potenti
caus
concern
relat
immunolog
safeti
restrict
biolog
immunemedi
immunotox
advers
effect
pharmaceut
subdivid
four
categori
name
immunosuppress
immunostimul
hypersensit
autoimmun
inde
essenti
bear
mind
clinic
manifest
well
modal
nonclin
well
clinic
safeti
evalu
markedli
distinct
depend
categori
immunotox
effect
consid
potent
immunosuppress
drug
clinic
use
decad
advers
event
associ
immunosuppress
well
character
two
major
clinic
consequ
immunosuppress
infecti
complic
virusassoci
neoplasia
immunocompromis
patient
includ
treat
immunosuppress
drug
affect
vast
varieti
bacteri
viral
fungal
parasit
infect
bresnihan
cunnan
fishman
infect
alway
frequent
often
sever
relaps
sometim
atyp
opportunist
overal
pathogen
involv
infect
develop
site
even
though
respiratori
gastrointestin
skin
infect
common
virusassoci
neoplasia
also
frequent
immunocompromis
subject
zafar
howel
gockerman
although
nonhodgkin
lymphoma
especi
b
lymphoma
usual
consid
anoth
hallmark
sever
druginduc
immunosuppress
everli
bloom
tsai
trofe
skin
cancer
includ
squamou
cell
cancer
kaposi
sarcoma
actual
frequent
pathogenesi
neoplasia
associ
immunosuppress
drug
larg
thought
link
dormant
subsequ
viral
infect
eg
epsteinbarr
viru
human
herp
viru
develop
facilit
immunosuppress
therefor
major
complic
immunosuppress
view
global
consequ
impair
resist
bodi
toward
pathogen
varieti
innat
andor
adapt
often
intric
immun
mechan
involv
host
defens
pathogen
predict
potenti
drug
candid
impair
resist
toward
pathogen
primarili
reli
immun
function
surprisingli
neither
ich
guidelin
ich
ich
guidelin
ich
requir
systemat
investig
immun
function
treat
anim
safeti
immunopharmacolog
studi
deem
help
gener
use
addit
inform
although
advers
effect
immunostimul
long
known
least
suspect
descot
full
confirm
obtain
introduct
potent
immunostimulatori
drug
particular
recombin
cytokin
monoclon
antibodi
clinic
frequent
advers
event
associ
immunostimulatori
drug
relat
cytokin
releas
descot
vial
depend
cytokinereleas
potenc
offend
drug
advers
event
manifest
flulik
reaction
moder
fever
shiver
myalgia
arthralgia
ii
acut
cytokin
syndrom
hyperpyrexia
mark
shiver
myalgia
arthralgia
well
cardiovascular
andor
neurolog
disturb
iii
cytokin
storm
combin
sever
clinic
manifest
acut
cytokin
syndrom
multiorgan
failur
especi
sever
acut
respiratori
syndrom
sra
acut
renal
failur
treatment
immunostimulatori
drug
shown
associ
frequent
autoimmun
diseas
strictli
ident
spontan
autoimmun
diseas
base
clinic
biolog
criteria
descot
potenti
immunostimulatori
drug
induc
frequent
hypersensit
reaction
unrel
allergen
long
recogn
larg
overlook
inde
patient
start
treatment
socal
immunopotenti
drug
eg
levamisol
long
report
develop
exacerb
prior
asthma
hay
fever
eczema
importantli
hypersensit
reaction
direct
immunostimulatori
drug
unrel
allergen
eg
microbi
environment
allergen
therefor
distinguish
genuin
druginduc
allergi
moreov
unequivoc
demonstr
patient
renal
carcinoma
treat
significantli
higher
incid
hypersensit
reaction
radiocontrast
media
zukiwski
et
al
final
larg
bodi
data
evid
potenti
immunostimulatori
drug
decreas
express
sever
gene
involv
cytochrom
system
result
signific
drug
interact
anim
extent
human
subject
therapeut
dose
descot
immunemedi
hypersensit
reaction
rather
frequent
advers
event
associ
drug
treatment
drug
allergi
pathogen
mechan
antigenspecif
immun
respons
involv
exquisit
recognit
memori
abil
immun
system
nonimmunemedi
hypersensit
reaction
mimic
immunemedi
hypersensit
reaction
least
extent
also
describ
deshazo
kemp
importantli
reaction
involv
specif
immun
respons
instead
releas
mediat
involv
immunemedi
hypersensit
reaction
via
pharmacolog
toxicolog
mechan
exampl
pseudoallerg
reaction
includ
direct
ie
nonigemedi
histamin
releas
direct
complement
activ
besid
frequent
autoimmun
diseas
observ
patient
treat
immunostimulatori
drug
druginduc
autoimmun
reaction
also
report
reaction
system
affect
mani
differ
target
bodi
eg
drug
lupu
syndrom
organspecif
character
highli
specif
autoantibodi
respons
eg
druginduc
myasthenia
autoimmun
hemolyt
anemia
global
reaction
rare
particular
organspecif
reaction
one
given
drug
typic
associ
one
given
type
autoimmun
reaction
underli
mechan
elucid
descot
regulatori
requir
nonclin
immunotox
evalu
pharmaceut
began
emerg
end
centuri
earli
guidanc
document
releas
ema
european
medicin
agenc
us
fda
us
food
drug
administr
includ
overtli
conflict
recommend
harmon
need
actual
achiev
ich
guidelin
ich
provid
core
current
requir
conduct
immunotox
studi
human
pharmaceut
revis
ich
guidelin
ich
offer
fairli
broad
recommend
immunotox
evalu
biotechnologyderiv
pharmaceut
ich
one
major
requir
ich
guidelin
systemat
incorpor
immunotox
evalu
standard
drug
develop
evalu
compris
weight
evid
review
base
result
standard
toxic
studi
includ
clinic
sign
particular
infect
tumor
caus
identifi
hematolog
anomali
eg
lymphopenialymphocytosi
histolog
chang
main
lymphoid
organ
bone
marrow
thymu
spleen
lymph
node
mucosaassoci
lymphoid
tissu
malt
ii
pharmacolog
properti
drug
candid
onand
offtarget
effect
immun
system
iii
intend
patient
popul
eg
immunocompromis
patient
iv
possibl
structur
similar
known
immunotoxic
v
drug
disposit
particular
high
concentr
test
articl
immun
cell
ich
weight
evid
review
conclud
caus
concern
identifi
addit
immunotox
studi
requir
contrast
caus
concern
either
one
mark
find
least
two
milder
find
among
item
list
identifi
addit
immunotox
studi
conduct
addit
immunotox
studi
typic
consist
repeateddos
least
toxic
studi
conduct
mostli
rodent
cours
select
immun
function
investig
tdepend
antibodi
respons
tdar
assay
wide
consid
firstlin
assay
global
simultan
assess
effect
drug
candid
antigen
present
helper
lymphocyt
function
b
lymphocytedepend
antibodi
product
immunotoxicologist
long
use
plaqueform
cell
pfc
assay
rodent
ladic
last
decad
antiklh
antibodi
respons
measur
elisa
emerg
prefer
assay
plitnick
herzyk
inde
antiklh
assay
use
rodent
well
nonrod
sharp
contrast
pfc
assay
use
rodent
klh
keyhol
limpet
hemocyanin
better
standard
antigen
sheep
erythrocyt
antigen
util
pfc
assay
antiklh
assay
also
less
time
consum
reproduc
result
seemingli
better
secondlin
immun
function
assay
includ
lymphocyt
subset
immunotyp
even
though
immun
function
assay
strictli
speak
measur
nk
cell
activ
use
either
gold
standard
cr
releas
assay
vitroex
vivo
flow
cytometri
techniqu
cellmedi
immun
model
lymphocyt
prolifer
assay
vitro
delayedtyp
dth
hypersensit
model
neutrophil
function
eg
chemotaxi
phagocytosi
assay
dietert
although
safeti
pharmacolog
studi
gener
perform
singl
dose
administr
imposs
prior
sensit
anim
requir
sever
assay
model
howev
avail
allow
shortterm
day
repeat
administr
assay
requir
singl
dose
administr
perform
context
dedic
safeti
immunopharmacolog
studi
shortterm
studi
eg
studi
endpoint
measur
first
last
administr
last
administr
case
assay
model
propos
see
tabl
straightforwardli
includ
safeti
immunopharmacolog
studi
context
immun
function
evalu
immunotoxicolog
safeti
pharmacolog
point
view
tdar
assay
pivot
earli
screen
one
obviou
drawback
antiklh
assay
compar
pfc
assay
standard
procedur
compris
minim
durat
day
antiklh
assay
vs
day
pfc
assay
measur
humor
respons
howev
white
sheth
peache
propos
shortterm
antiklh
igm
screen
assay
mous
altern
pfc
assay
mice
inject
mg
klhmous
via
intraven
rout
sera
collect
day
measur
antiklh
igm
elisa
refer
immunosuppress
drug
cyclophosphamid
rang
mgkgday
azathioprin
mgkgday
cyclosporin
mgkgday
induc
significantli
dosedepend
decreas
antiklh
igm
level
use
dose
rang
similar
trend
observ
pfc
assay
although
latter
assay
slightli
sensit
antiklh
igm
assay
high
level
predict
pfc
assay
long
demonstr
wide
panel
immunosuppress
agent
luster
et
al
noteworthi
immunosuppress
potenti
cyclosporin
serendipit
discov
thank
systemat
use
pfc
assay
borel
feurer
gubler
white
et
al
found
similar
effect
shortterm
antiklh
igm
mous
screen
assay
prototyp
immunosuppress
drug
whose
effect
wellcharacter
human
support
conclus
assay
like
predict
pfc
assay
addit
screen
assay
offer
advantag
use
tdepend
antigen
name
klh
antigen
increasingli
use
tdar
assay
includ
dedic
immunotox
studi
later
stage
develop
cellmedi
immun
straightforwardli
assess
use
either
dth
model
mice
rat
contact
hypersensit
model
mice
day
sensit
challeng
rodent
dth
typic
measur
increas
footpad
thick
footpad
assay
induc
elicit
inject
select
antigen
eg
srbc
bovin
serum
albumin
one
hind
footpad
anim
previous
sensit
subcutan
inject
antigen
back
abdomen
contact
hypersensit
measur
increas
ear
thick
ear
assay
induc
elicit
applic
potent
contact
sensit
eg
oxazolon
dinitrofluorobenzen
picryl
chlorid
side
one
ear
anim
previous
sensit
prior
topic
applic
sensit
side
contralater
ear
keep
wellknown
clinic
activ
human
immunosuppress
drug
shown
induc
reduc
increas
footpad
ear
thick
support
conclus
model
suitabl
earli
predictor
unexpect
unintend
immunosuppress
potenti
drug
candid
descot
tedon
evreux
smith
white
neutrophil
function
primarili
includ
chemotaxi
phagocytosi
latter
mainli
consist
bacteri
ingest
oxid
burst
variou
techniqu
avail
measur
neutrophil
function
endpoint
either
vitro
vivo
besid
mani
assay
use
research
purpos
classic
techniqu
use
boyden
chamber
agaros
evalu
chemotaxi
bacteri
ingest
count
chemiluminesc
phagocytosi
either
time
consum
bias
individu
subject
andor
requir
technic
skill
andor
expens
equip
howev
flow
cytometri
techniqu
use
measur
chemotaxi
phagocytosi
lehmann
sorn
halstensen
consid
well
suit
safeti
immunopharmacolog
studi
horand
cretinon
condevaux
descot
noteworthi
flow
cytometri
techniqu
routin
use
clinic
immunolog
laboratori
test
human
subject
especi
children
suspect
inborn
defect
capac
ingest
bacteria
mount
oxid
burst
adequ
chemotact
respons
although
databas
pharmaceut
use
techniqu
still
limit
avail
result
suggest
suffici
predict
freebern
bigwarf
price
haggerti
submit
public
limit
experi
avail
regard
nonclin
evalu
immunostimulatori
effect
howev
data
obtain
sever
drug
eg
levamisol
cimetidin
rodent
monoclon
antibodi
nonhuman
primat
suggest
tdar
assay
also
use
predict
immunostimulatori
potenti
human
pharmaceut
descot
piccotti
nowaday
cytokin
releas
consid
reliabl
predict
vitro
assay
use
human
cell
instead
vivo
monkey
shown
poorli
relev
due
speciesspecif
differ
eastwood
et
al
recent
immunostimulatori
nanoparticl
report
enhanc
ovalbumin
sensit
wellestablish
experiment
model
respiratori
allergi
mice
increas
respiratori
respons
ovalbumin
de
haar
hass
bol
bleumink
pieter
model
could
consid
assess
risk
frequent
hypersensit
reaction
toward
unrel
allergen
patient
treat
immunostimulatori
drug
candid
immunemedi
hypersensit
reaction
clearli
outsid
scope
safeti
immunopharmacolog
studi
contrast
pseudoallerg
reaction
due
inadvert
releas
mediat
via
pharmacolog
toxicolog
mechan
histamin
releas
investig
measur
histamin
blood
level
follow
singl
dose
inject
test
articl
dog
monkey
human
gued
papich
rude
rider
interestingli
histaminereleas
potenc
morphin
morphin
deriv
anim
model
found
correl
human
find
direct
non
antigenspecif
activ
complement
cascad
evidenc
measur
level
either
vitro
vivo
rat
minipig
dog
human
szebeni
interestingli
correl
measur
level
cardiovascular
chang
studi
vivo
szebeni
et
al
use
model
pig
possibl
compar
predict
risk
pseudoallerg
reaction
via
direct
nonantigen
specif
activ
complement
cascad
human
patient
treat
pegyl
liposom
formul
anticanc
drug
doxorubicin
final
flow
cytometri
use
evid
basophil
activ
ebo
et
al
even
though
techniqu
seemingli
rare
use
anim
model
van
scott
et
al
despit
rare
claim
system
evalu
immunotox
particularli
immunosuppress
potenti
drug
candid
warrant
snodin
larg
bodi
evid
show
data
obtain
anim
studi
fairli
well
correl
clinic
find
human
fact
unexpect
advers
immunemedi
clinic
find
report
human
like
due
inadequ
insuffici
immunotox
assess
preclin
studi
suggest
author
experi
along
thirti
year
postmarket
drug
surveil
preclin
safeti
activ
improv
current
situat
pharmacolog
studi
therefor
consid
help
immunolog
safeti
evalu
pharmaceut
least
earli
screen
mechanist
studi
standard
toxic
studi
deem
insuffici
reliabl
predictor
immunotox
potenti
drug
candid
due
lack
systemat
investig
chang
immun
function
germolec
et
al
inde
chang
histolog
lymphoid
organ
nevertheless
associ
significantli
decreas
immun
respons
therefor
assum
insuffici
assess
potenti
drug
candid
alter
immun
function
may
one
lead
caus
poor
predict
nonclin
studi
even
though
ich
guidelin
requir
weight
evid
review
conduct
prior
phase
iii
clinic
trial
ich
late
discoveri
advers
immun
potenti
drug
candid
prove
problemat
eg
gono
go
decis
reorient
drug
develop
alreadi
mention
tdar
assay
consid
best
tool
earli
screen
global
assess
antigen
present
helper
lymphocyt
function
b
lymphocytedepend
antibodi
product
pfc
antiklh
igm
assay
use
earli
predict
immunosuppress
potenti
drug
candid
follow
shortterm
administr
ie
day
depend
result
tdar
assay
mechan
action
drug
candid
intend
futur
therapeut
indic
assay
model
use
earli
safeti
immunopharmacolog
assess
inde
dth
model
focu
cellmedi
immun
respons
wherea
neutrophil
function
assay
provid
use
inform
select
effect
phagocytosi
oxid
burst
chemotaxi
depend
select
assay
alreadi
mention
fairli
good
concord
result
obtain
assay
provid
actual
mechanist
studi
essenti
identifi
caus
concern
ich
requir
mechanist
studi
biolog
intend
inadvert
target
immun
system
ich
also
recommend
human
pharmaceut
known
earli
screen
suspect
alter
immun
respons
mechan
action
pharmacolog
inde
mechanist
studi
pivot
select
relev
secondlin
endpointsassay
case
case
besid
firstlin
tdar
assay
includ
addit
immunotox
studi
last
least
mechanist
studi
deem
critic
design
translat
immun
safeti
evalu
program
essenti
extrapol
anim
human
assess
clinic
trial
descot
submit
public
overview
intend
provid
definit
pictur
safeti
immunopharmacolog
studi
instead
propos
start
point
draw
perspect
futur
develop
time
area
drug
safeti
assess
model
assay
briefli
describ
well
establish
nevertheless
seldom
includ
preclin
safeti
assess
drug
candid
although
fairli
good
concord
result
compar
human
find
often
retrospect
safeti
immunopharmacolog
studi
believ
primarili
help
improv
immun
safeti
assess
either
smallmolecularweight
drug
candid
intend
unexpect
immunomodulatori
activ
biolog
whose
immunogen
preclud
conduct
standard
repeateddos
toxic
studi
suffici
durat
conclus
made
recent
use
larg
panel
monoclon
antibodi
fusion
protein
neither
mice
nonhuman
primat
good
predict
valu
human
advers
effect
might
partial
true
limit
safeti
immunopharmacolog
result
gener
biolog
therefor
conclus
taken
addit
evid
safeti
immunopharmacolog
studi
inde
includ
systemat
preclin
immun
safeti
assess
novel
biolog
also
obviou
much
remain
done
design
valid
adequ
assay
model
assess
immun
safeti
biolog
relev
convent
anim
speci
avail
